



MOWOOT is a growth stage **medical device company** targeting **intestinal transit disorders** with a purely physical, **non-drug, non-invasive solution.**

Slow intestinal Transit & Chronic Constipation a huge unmet need:

- **High Prevalence: 250M people in EU & USA** (24% of Gen Pop / 60% of elderly / 80% of Neurol. Patients)
- **Severe Secondary Problems:** from embarrassing (incontinence) to life threatening (cancer; prolapse; ...)
- **High Health Economic Burden** outlined as much as \$100B annually in EU & USA
- **Current Approaches have Side Effects & are Expensive** (laxatives, drugs, enemas or surgical solutions)

Novel non-drug, non-invasive solution:



Intestinal Transit Management System:

- Purely physical stimulation of gut motility & secretion
- Clinically proven results with **only 10-20 minutes once daily** treatment
- Lightweight belt is easy to put on (over clothes)
- Patented *Exo-peristalsis Technology* resembles professional manual colonic massage by therapists



Market:

Beachhead Target Indication:

- **Neurogenic Bowel Disorder (NBD)**
Global Annual Market \$1.74B w/ CAGR 3,5%

Future Indications:

- **Opioid-Induced-Constipation (OIC)**
Global Annual Market \$3.7B w/ CAGR 32%
- **Idiopathic Chronic Constipation (ICC)**
Global Annual Market \$12.6B w/ CAGR 7.1%
- **Health & Wellness (OTC device)**
Global Annual Market \$64B w/ CAGR 4.4%

Executive Team:



Dr. Markus Wilhelms, CEO
PhD, Expert in Needs-driven Innovation



Dr. Immaculada Herrero, CSO
PhD, Expert in Clinical Studies



Marc Benet, CRMO
MSc, Expert in Med. Dev. QMS & Regulatory



Dr. Angel Calzada, CTO
PhD, Expert in Software Dev. & Supply Chain MGNT



Josep Molinero, CFO
MBA, MSc STMG, Expert in Finance

Plus:

- **Intl. Advisory Board**
Experienced Medtech Entrepreneurs
- **Medical KOL**
in Neurogenic Bowel Dysfunction

Milestones:

www.mowoot.com

- ✓ **Product:** • on the market & pipeline dev.
- ✓ **Regulatory:** • CE (med. Dev. Class IIa)
• ISO13485 certification (MDR)
- ✓ **IP:** • PCT/IB2015/001576
- ✓ **Clinical:** • 3 published pilot studies
• [1 published multicenter study](#)
- ✓ **Biz Dev:** • First sales & distribution partners in GER, UK, NL & DK
- ✓ **Market Acceptance:** • Device in use in 30 EU KOL centers
• State-of-the-Art in "Neurogenic Bowel" SCI clinical guideline (GER)
• Majority of sales already reimbursed by private & public healthcare providers
• *Complete public reimbursement expected H2 2021 (GER) & H2 2022 (UK)*

€3.9M
Raised to Date

€343K
Revenue in 2020

8
Current Head Count



PHASE II

Contact: Markus Wilhelms – CEO & Co-founder - markus@mowoot.com